← Back to Screener
AN2 Therapeutics, Inc. Common Stock (ANTX)
Price$4.21
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)285.00%
Price vs S&P 500 (4W)-12.45%
VGM Score81.21
Market Capitalization$155.95M
All Metrics
Book Value / Share (Quarterly)$2.27
P/TBV (Annual)5.38x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.87
Price vs S&P 500 (YTD)268.89%
EPS (TTM)$-1.10
10-Day Avg Trading Volume0.25M
EPS Excl Extra (TTM)$-1.10
EPS (Annual)$-1.16
ROI (Annual)-66.29%
Cash / Share (Quarterly)$2.37
ROA (Last FY)-56.78%
EBITD / Share (TTM)$-1.19
ROE (5Y Avg)-51.73%
Cash Flow / Share (Annual)$-1.09
P/B Ratio1.91x
P/B Ratio (Quarterly)1.50x
Net Income / Employee (Annual)$-1,675,000
ROA (TTM)-47.25%
EPS Incl Extra (Annual)$-1.16
Current Ratio (Annual)6.87x
Quick Ratio (Quarterly)15.33x
3-Month Avg Trading Volume1.04M
52-Week Price Return257.85%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.67
52-Week High$6.91
EPS Excl Extra (Annual)$-1.16
26-Week Price Return300.93%
Quick Ratio (Annual)6.65x
13-Week Price Return308.49%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)15.73x
Enterprise Value$102.46M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.12
3-Month Return Std Dev235.54%
Net Income / Employee (TTM)$-1,645,400
ROE (Last FY)-66.29%
EPS Basic Excl Extra (Annual)$-1.16
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.10
ROI (TTM)-52.35%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.92
Price vs S&P 500 (52W)229.65%
Year-to-Date Return279.82%
5-Day Price Return-10.72%
EPS Normalized (Annual)$-1.16
ROA (5Y Avg)-46.42%
Month-to-Date Return-4.84%
EBITD / Share (Annual)$-1.26
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-51.73%
EPS Basic Excl Extra (TTM)$-1.10
P/TBV (Quarterly)3.69x
P/B Ratio (Annual)0.59x
Book Value / Share (Annual)$1.94
Price vs S&P 500 (13W)298.74%
Beta-0.99x
Revenue / Share (TTM)$0.00
ROE (TTM)-52.35%
52-Week Low$1.00
mGradeA
vgmGradeA
Show chart for
Earnings Surprise History
Q1 26-0.29est. -0.23
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANTXAN2 Therapeutics, Inc. Common Stock | — | — | A | $4.21 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
AN2 Therapeutics develops small molecule therapeutics using proprietary boron chemistry, targeting infectious diseases and oncology with significant unmet medical needs. Its pipeline includes programs for Chagas disease, non-tuberculous mycobacterial infections, and melioidosis, with additional early-stage oncology initiatives.